15353-j-veluchamy

32 | Chapter 1 72. Dolstra H, Roeven MW, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients. Clin Cancer Res (2017). Epub 2017/03/11. doi: 10.1158/1078-0432. ccr-16-2981. PubMed PMID: 28280089. 73. Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine (2016) 8 (357):357ra123-357ra123. doi: 10.1126/scitranslmed.aaf2341. 74. Curti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, et al. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. Clin Cancer Res (2016) 22 (8):1914-21. Epub 2016/01/21. doi: 10.1158/1078-0432.ccr-15-1604. PubMed PMID: 26787753. 75. Shaffer BC, Le Luduec J-B, Forlenza C, Jakubowski AA, Perales M-A, Young JW, et al. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation (2016) 22 (4):705-9. doi: http://dx.doi.org/10.1016/j.bbmt.2015.12.028. 76. Yang Y, Lim O, Kim TM, Ahn YO, Choi H, Chung H, et al. Phase I Study of Random Healthy Donor-Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors. Cancer immunology research (2016) 4 (3):215-24. Epub 2016/01/21. doi: 10.1158/2326-6066.cir-15-0118. PubMed PMID: 26787822. 77. Rubnitz JE, Inaba H, Kang G, Gan K, Hartford C, Triplett BM, et al. Natural killer cell therapy in children with relapsed leukemia. Pediatr Blood Cancer (2015) 62 (8):1468-72. Epub 2015/05/01. doi: 10.1002/pbc.25555. PubMed PMID: 25925135; PubMed Central PMCID: PMCPMC4634362. 78. Kottaridis PD, North J, Tsirogianni M, Marden C, Samuel ER, Jide-Banwo S, et al. Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial. PLOS ONE (2015) 10 (6):e0123416. doi: 10.1371/journal.pone.0123416. 79. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, et al. Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo In High-Risk Relapsed Multiple Myeloma Patients. Journal of immunotherapy (Hagerstown, Md : 1997) (2015) 38 (1):24-36. doi: 10.1097/ CJI.0000000000000059. PubMed PMID: PMC4352951. 80. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood (2014) 123 (25):3855-63. doi: 10.1182/blood-2013-10-532531. PubMed PMID: PMC4064329. 81. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 17 (4):678-89. Epub 2011/02/18. doi: 10.1158/1078-0432.ccr-10-2173. PubMed PMID: 21325295. 82. Larsen SK, Gao Y, Basse PH. NK Cells in the TumorMicroenvironment. Critical reviews in oncogenesis (2014) 19 (0):91-105. PubMed PMID: PMC4062922.